Harrow reaffirms 2025 revenue guidance of $270-280M, promotes Sullivan to CCO, settles CA regulatory matters

HARROW, INC.

2025-FY EPS reported -$0.14 vs consensus $0.38 ▼ miss (-137.2%)

Reaffirmed FY2025 revenue guidance of $270-280 million; full-year results expected in early March.
Patrick Sullivan promoted to CCO; $425k base salary, 40% target bonus, 40,000 RSUs vesting on $230M quarterly branded revenue.
VEVYE sales force to double to ~100 territories by Memorial Day; TRIESENCE surgical sales force also doubling.
ImprimisRx settled with CA Board of Pharmacy for ~$157k fine and voluntarily exited CA market; not financially material.
MELT-300 NDA submission on track for H1 2027; MELT-210 NDA on track.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.